Ortega-González Carlos, Parra Adalberto, Barra Rosalba, Aranda Carlos, Ramírez Dana, Di Castro Paolo, Castro Ivone, Zambrana Marcela, Coria Irma
Instituto Nacional de Perinatología, Hospital General, Secretaria de Salud, Mexico City, Mexico.
Endocr Pract. 2002 Mar-Apr;8(2):89-95. doi: 10.4158/EP.8.2.89.
To investigate whether the serum prolactin (PRL) response to a dopamine antagonist was different in nonobese, euthyroid women with malignant or benign breast tumors in comparison with healthy women, considering their age at first full-term pregnancy or their nulliparity.
Serum PRL concentrations before and 60, 90, and 120 minutes after oral administration of metoclopramide (10 mg) were studied in 122 nonobese, nonsmoking, euthyroid women: 28 who had invasive breast cancer, stage I or II (group 1), 34 who had benign breast disease (group 2), and 60 who were clinically healthy (group 3). These three main groups were subdivided into early and late parous women (< or = 25 and >25 years, respectively) and nulliparous women, and the menopausal status was also considered.
Early parous women with invasive breast cancer (both premenopausal and postmenopausal) and early parous premenopausal women with benign breast disease had significantly higher serum PRL concentrations in response to administration of metoclopramide (P<0.05) and a greater area under the PRL curve (P<0.05) than those observed in early parous healthy women. No other significant differences in the serum PRL response were noted between or within groups.
The results of this study suggest the existence of an increased hypothalamic dopaminergic tone in early parous women but not in late parous or nulliparous women with malignant or benign breast tumors in comparison with similar healthy women. This finding may represent an adaptive protective mechanism attempting to prevent persistently increased serum PRL concentrations, a factor that could adversely affect the clinical evolution of the disease.
研究非肥胖、甲状腺功能正常且患有恶性或良性乳腺肿瘤的女性与健康女性相比,血清催乳素(PRL)对多巴胺拮抗剂的反应是否存在差异,同时考虑她们首次足月妊娠的年龄或未生育情况。
对122名非肥胖、不吸烟、甲状腺功能正常的女性进行研究,测定她们口服甲氧氯普胺(10毫克)前及服药后60、90和120分钟时的血清PRL浓度。这122名女性分为三组:28名患有I期或II期浸润性乳腺癌的女性(第1组),34名患有良性乳腺疾病的女性(第2组),以及60名临床健康的女性(第3组)。这三个主要组又进一步细分为初产早(分别为≤25岁和>25岁)和初产晚的女性以及未生育女性,同时还考虑了绝经状态。
患有浸润性乳腺癌的初产早的女性(包括绝经前和绝经后)以及患有良性乳腺疾病的初产早的绝经前女性,在服用甲氧氯普胺后血清PRL浓度显著高于初产早的健康女性(P<0.05),PRL曲线下面积也更大(P<0.05)。组间或组内未发现血清PRL反应的其他显著差异。
本研究结果表明,与类似健康女性相比,初产早的女性下丘脑多巴胺能张力增加,而患有恶性或良性乳腺肿瘤的初产晚或未生育女性则没有这种情况。这一发现可能代表一种适应性保护机制,试图防止血清PRL浓度持续升高,而血清PRL浓度持续升高可能会对疾病的临床进展产生不利影响。